BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 34975756)

  • 21. Glucocorticoid-induced Osteoporosis.
    Whittier X; Saag KG
    Rheum Dis Clin North Am; 2016 Feb; 42(1):177-89, x. PubMed ID: 26611558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of bisphosphonates for prevention of fracture related to glucocorticoid-induced osteoporosis in Malaysia.
    Mohd-Tahir NA; Thomas P; Mohamed-Said MS; Makmor-Bakry M; Li SC
    Int J Rheum Dis; 2018 Mar; 21(3):647-655. PubMed ID: 29105349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Update on glucocorticoid-induced osteoporosis.
    Maricic M
    Rheum Dis Clin North Am; 2011 Aug; 37(3):415-31, vi. PubMed ID: 22023900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of care delivery by a novel multidisciplinary bone health clinic for patients at risk of glucocorticoid-induced osteoporosis.
    Abdullah H; Koller G; Zuna I; Yuksel N; Charrois T; Mandhane R; Cotton K; Danilak M; Bell H; Ye C
    Arch Osteoporos; 2021 Jul; 16(1):108. PubMed ID: 34347188
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Assessment of the treatment of glucocorticoid-induced osteoporosis].
    Asano S; Suzuki A
    Clin Calcium; 2013 Mar; 23(3):401-8. PubMed ID: 23445894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in treatment of glucocorticoid-induced osteoporosis.
    Hsu E; Nanes M
    Curr Opin Endocrinol Diabetes Obes; 2017 Dec; 24(6):411-417. PubMed ID: 28857847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of 18 anti-osteoporotic drugs in the treatment of patients with osteoporosis caused by glucocorticoid: A network meta-analysis of randomized controlled trials.
    Liu Z; Zhang M; Shen Z; Ke J; Zhang D; Yin F
    PLoS One; 2020; 15(12):e0243851. PubMed ID: 33326444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapies for Preventing Bone Loss with Glucocorticoid Treatment.
    Agarwal A; Adachi JD
    Curr Osteoporos Rep; 2021 Feb; 19(1):34-39. PubMed ID: 33409989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vitamin D and bisphosphonate therapy in systemic lupus erythematosus patients who receive glucocorticoids: are we offering the best care?
    Sapkota S; Baig S; Hess T; O'Connell AM; Menk J; Shyne M; Fazeli P; Ensrud K; Shmagel A
    Lupus; 2020 Mar; 29(3):263-272. PubMed ID: 31996109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study.
    Rossini M; Viapiana O; Vitiello M; Malavolta N; La Montagna G; Maddali Bongi S; Di Munno O; Nuti R; Manzini CU; Ferri C; Bogliolo L; Mathieu A; Cantatore F; Del Puente A; Muratore M; Grassi W; Frediani B; Saviola G; Delvino P; Mirone L; Ferraccioli G; Tripi G; Piazza I; Gatti D
    Reumatismo; 2017 May; 69(1):30-39. PubMed ID: 28535619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
    Saag KG; Shane E; Boonen S; Marín F; Donley DW; Taylor KA; Dalsky GP; Marcus R
    N Engl J Med; 2007 Nov; 357(20):2028-39. PubMed ID: 18003959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Mechanisms and therapeutics of glucocorticoid-induced osteoporosis].
    Kaneko K; Kawai S
    Nihon Rinsho Meneki Gakkai Kaishi; 2011; 34(3):138-48. PubMed ID: 21720102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.
    Buckley L; Guyatt G; Fink HA; Cannon M; Grossman J; Hansen KE; Humphrey MB; Lane NE; Magrey M; Miller M; Morrison L; Rao M; Robinson AB; Saha S; Wolver S; Bannuru RR; Vaysbrot E; Osani M; Turgunbaev M; Miller AS; McAlindon T
    Arthritis Rheumatol; 2017 Aug; 69(8):1521-1537. PubMed ID: 28585373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis: the TOWER-GO study.
    Tanaka I; Tanaka Y; Soen S; Oshima H
    J Bone Miner Metab; 2021 May; 39(3):446-455. PubMed ID: 33211212
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk and management of osteoporosis due to inhaled, epidural, intra-articular or topical glucocorticoids.
    Anastasilakis AD; Naciu AM; Yavropoulou MP; Paccou J
    Joint Bone Spine; 2023 Dec; 90(6):105604. PubMed ID: 37399940
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Vitamin K2 as a potential therapeutic agent for glucocorticoid-induced osteoporosis].
    Tanana I; Oshima H
    Clin Calcium; 2006 Nov; 16(11):1851-7. PubMed ID: 17079852
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis.
    Amiche MA; Albaum JM; Tadrous M; Pechlivanoglou P; Lévesque LE; Adachi JD; Cadarette SM
    Osteoporos Int; 2016 Jun; 27(6):1989-98. PubMed ID: 26782683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anabolic therapy in glucocorticoid-induced osteoporosis.
    Sambrook PN
    N Engl J Med; 2007 Nov; 357(20):2084-6. PubMed ID: 18003966
    [No Abstract]   [Full Text] [Related]  

  • 39. [Secondary osteoporosis UPDATE. Clinical significance of glucocorticoid-induced osteoporosis].
    Suzuki Y; Sato S
    Clin Calcium; 2010 May; 20(5):645-53. PubMed ID: 20445275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update on Glucocorticoid Induced Osteoporosis.
    Cho SK; Sung YK
    Endocrinol Metab (Seoul); 2021 Jun; 36(3):536-543. PubMed ID: 34107602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.